Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dah Chong Hong (DCH), often referred to as Dachang Trading in mainland China, is a prominent Asian conglomerate specializing in motor and consumer goods distribution, with a robust healthcare division known as DCH Auriga. Following the acquisition of Li & Fung's healthcare distribution business in 2016, DCH Auriga has become a leading provider of market access and supply chain solutions for the pharmaceutical and life sciences industries. The company offers comprehensive services including regulatory compliance, clinical trial logistics, and commercial outsourcing across Greater China and Southeast Asia. DCH Auriga manages a wide array of products, from high-value specialty medicines and vaccines to medical devices and diagnostics. As a subsidiary of CITIC Pacific, DCH provides global healthcare brands with a sophisticated regional network and advanced cold chain infrastructure. The company is a critical partner for multinational firms seeking to expand their footprint in the complex Asian healthcare market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dachang Trading.